Merck has received a significant endorsement from the CHMP for KEYTRUDA®, paving the way for a new subcutaneous administration option and an expanded cancer indication. This development not only enhances patient convenience but also reinforces Merck’s position in the competitive oncology landscape.
RAHWAY, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for KEYTRUDA® (pembrolizumab), which if approved would be marketed in
Source: Original Press Release
